Pain in the Gut: Next Generation Therapy for Acid Reflux in the Pipeline

In this episode, we are joined by Kjell Anderson, Chief Scientific Officer at Cinclus Pharma, to discuss a novel treatment for acid reflux.

Millions of people worldwide grapple with acid reflux, which may progress to gastroesophageal reflux disease (GERD). Chronic acid exposure in the esophagus can lead to discomfort, inflammation, and even erosions—tissue damage that can severely affect a patient’s quality of life. While lifestyle modifications and standard proton pump inhibitors (PPIs) offer relief for some, they are not always effective for moderate to severe forms of GERD, largely due to limited coverage over a 24-hour period.

In this episode we discuss a next-generation compound—linaprazan glurate—designed to address these unmet needs. By providing a longer and more controlled suppression of gastric acid than traditional PPIs, this competitive, reversible inhibitor holds promise for patients whose symptoms or erosions persist despite standard therapy. With a Phase 2 study completed and Phase 3 on the horizon, linaprazan glurate could mark a turning point for those in search of more consistent relief.

Want to Know More?

Join us in this conversation hosted by Martina Ribar Hestericová, for the full story about the science behind acid reflux, challenges in clinical development, and how a novel therapy like linaprazan glurate may reshape the future of GERD treatment.